Physician profile
Anmol Baranwal
NPI 1083008643
$4,306.76
in general payments reported to CMS, 2019-2025
45 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $65.12 · 2022: $528 · 2023: $963 · 2024: $1,563 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,565.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $350.25 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $322.18 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $315.77 | 2023-2025 | Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $276.70 | 2019-2024 | Opdivo, Eliquis |
| Myriad Genetic Laboratories, INC. | $198.55 | 2022-2024 | Myrisk |
| Janssen Biotech, INC. | $188.07 | 2022-2025 | Rybrevant, Carvykti |
| Gilead Sciences, INC. | $180.45 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $158.90 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Array Biopharma INC | $158.54 | 2023-2025 | Mektovi, Lorbrena, Xalkori |
| Takeda Pharmaceuticals U.S.A., INC. | $155.99 | 2019-2024 | Fruzaqla |
| Sobi, INC | $152.72 | 2024-2025 | |
| Celgene Corporation | $148.85 | 2023-2025 | Pomalyst, Reblozyl, Opdualag |
| Genzyme Corporation | $137.11 | 2022-2024 | |
| Abbvie INC. | $131.91 | 2022-2025 | Venclexta |
| Astellas Pharma US INC | $128.92 | 2021-2025 | Vyloy, Xtandi, Xospata |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $119.99 | 2022-2025 | Jakafi |
| Daiichi Sankyo INC. | $104.58 | 2022-2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $92.17 | 2023-2025 | Monoferric |
| Lilly USA, LLC | $86.28 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $79.78 | 2024-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $70.57 | 2023-2024 | Orgovyx |
| Glaxosmithkline, LLC. | $67.10 | 2022-2024 | Jemperli, Zejula |
| Adc Therapeutics America, INC. | $60.18 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $56.49 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $55.51 | 2019-2023 | Lumakras |
| Cti Biopharma Corp. | $51.24 | 2022-2023 | Vonjo |
| Seagen INC. | $48.02 | 2022-2023 | Adcetris, Padcev |
| Epizyme, INC. | $44.25 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $42.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.72 | 2023-2024 | Gilotrif |
| Mirati Therapeutics, INC. | $24.06 | 2024 | Krazati |
| Blueprint Medicines Corporation | $22.94 | 2024 | Ayvakit |
| Pharmaessentia USA Corporation | $22.44 | 2025 | Besremi |
| Puma Biotechnology, INC. | $22.00 | 2024 | |
| Caris Mpi, INC. | $20.20 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $20.12 | 2024 | Xpovio |
| Menarini Silicon Biosystems, INC. | $19.71 | 2025 | |
| G1 Therapeutics, INC. | $19.57 | 2022 | |
| Stemline Therapeutics INC. | $17.73 | 2024 | Orserdu |
| Sirtex Medical INC | $16.67 | 2023 | Sir-Spheres Microspheres |
| Myovant Sciences INC. | $16.63 | 2022 | |
| Springworks Therapeutics, INC. | $15.39 | 2025 | Ogsiveo |
| Bayer Healthcare Pharmaceuticals INC. | $14.97 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.20 | 2024 | |
| Eisai INC. | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anmol Baranwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.